The European Commission announced on Monday a new agreement for the acquisition of vaccines against Covid-19, in this case with the German pharmaceutical company CureVac for the purchase of up to 400 million doses when authorized, while continuing to negotiate with Moderna to seal a pact with the US firm.
The head of the Community Executive, Ursula von der Leyen, has assured in a statement without questions from the press that the agreement with CureVac will be authorized this Tuesday, so the signing will take place in the coming weeks.
The German has also said that Brussels continues to negotiate with the American company Moderna, which this Monday announced that its vaccine has an efficacy of 94.5%, as observed in the first analyzes.
The one with CureVac It is the fifth agreement that the European Commission closes for the acquisition of vaccines once proven to be safe and effective, following deals with AstraZeneca, Sanofi / GSK, Johnson & Johnson, and Pfizer / BioNTech. The first three are already signed, while the fourth has yet to be signed by both parties.
In addition, the community Executive reached a preliminary agreement with Moderna in August for the acquisition of 80 million doses of its vaccine and has “exploratory talks” with other firms.
“We do not know which vaccine will end up being safe and effective. The European Medicines Agency will authorize them after conducting a solid analysis, so we need to have a wide portfolio of vaccines based on different technologies “, explained Von der Leyen.